Comparison Overview

SpringWorks Therapeutics

VS

MilliporeSigma

SpringWorks Therapeutics

100 Washington Blvd, Stamford, Connecticut, 06902, US
Last Update: 2025-03-05 (UTC)
View Profile
Between 750 and 799
http://www.springworkstx.com

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. Founded in 2017, SpringWorks has a diversified targeted oncology pipeline spanning solid tumors and hematological cancers, including clinical trials in rare tumor types and highly prevalent, genetically defined cancers.

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 388
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

MilliporeSigma

400 Summit Drive, Burlington, MA, 01803, US
Last Update: 2025-05-06 (UTC)
Between 750 and 799
http://www.sigmaaldrich.com

Together with our colleagues, customers and stakeholders, we impact life and health with science. Before researchers can make scientific breakthroughs, they must have access to state-of-the-art tools, services and expertise to perform experiments and engineer new products. That’s where we come in. We offer one of the broadest portfolios in the industry for scientists, best-in-class products for pharmaceutical development and manufacturing, and a fully integrated service organization to support CDMO and contract testing across traditional and novel modalities. Our vision is a world where our innovative products, services and digital offerings help create solutions for people globally and a sustainable future for generations to come. The life science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the US and Canada. Merck KGaA, Darmstadt, Germany is a global science and technology company with around 60,000 employees in more than 66 countries. Intended only for US/CA visitors.

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 10,332
Subsidiaries: 3
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/springworks-therapeutics.jpeg
SpringWorks Therapeutics
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/milliporesigma.jpeg
MilliporeSigma
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
SpringWorks Therapeutics
100%
Compliance Rate
0/4 Standards Verified
MilliporeSigma
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for SpringWorks Therapeutics in 2025.

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for MilliporeSigma in 2025.

Incident History — SpringWorks Therapeutics (X = Date, Y = Severity)

SpringWorks Therapeutics cyber incidents detection timeline including parent company and subsidiaries

Incident History — MilliporeSigma (X = Date, Y = Severity)

MilliporeSigma cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/springworks-therapeutics.jpeg
SpringWorks Therapeutics
Incidents

No Incident

https://images.rankiteo.com/companyimages/milliporesigma.jpeg
MilliporeSigma
Incidents

No Incident

FAQ

MilliporeSigma company demonstrates a stronger AI Cybersecurity Score compared to SpringWorks Therapeutics company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, MilliporeSigma company has disclosed a higher number of cyber incidents compared to SpringWorks Therapeutics company.

In the current year, MilliporeSigma company and SpringWorks Therapeutics company have not reported any cyber incidents.

Neither MilliporeSigma company nor SpringWorks Therapeutics company has reported experiencing a ransomware attack publicly.

Neither MilliporeSigma company nor SpringWorks Therapeutics company has reported experiencing a data breach publicly.

Neither MilliporeSigma company nor SpringWorks Therapeutics company has reported experiencing targeted cyberattacks publicly.

Neither SpringWorks Therapeutics company nor MilliporeSigma company has reported experiencing or disclosing vulnerabilities publicly.

Neither SpringWorks Therapeutics nor MilliporeSigma holds any compliance certifications.

Neither company holds any compliance certifications.

MilliporeSigma company has more subsidiaries worldwide compared to SpringWorks Therapeutics company.

MilliporeSigma company employs more people globally than SpringWorks Therapeutics company, reflecting its scale as a Biotechnology Research.

Neither SpringWorks Therapeutics nor MilliporeSigma holds SOC 2 Type 1 certification.

Neither SpringWorks Therapeutics nor MilliporeSigma holds SOC 2 Type 2 certification.

Neither SpringWorks Therapeutics nor MilliporeSigma holds ISO 27001 certification.

Neither SpringWorks Therapeutics nor MilliporeSigma holds PCI DSS certification.

Neither SpringWorks Therapeutics nor MilliporeSigma holds HIPAA certification.

Neither SpringWorks Therapeutics nor MilliporeSigma holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
References
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References